Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

NCT02489968 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

880

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: empagliflozin 10 mg + linagliptin 5 mg
DRUG: empagliflozin 10 mg
DRUG: empagliflozin 25 mg + linagliptin 5 mg
DRUG: empagliflozin 25 mg
DRUG: Placebo

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]